A deimmunized and pharmacologically optimized Toll-like receptor 5 agonist for therapeutic applications

A deimmunized and pharmacologically optimized Toll-like receptor 5 agonist for therapeutic applications

Mett et al. describe development of GP532, a substantially deimmunized derivative of Toll-like receptor 5 (TLR5) agonist entolimod. GP532 has mutations eliminating key B- and T-cell epitopes and an inflammasome-activating domain yet remains a potent NF-κB activator with biological effects similar to...

Full description

Saved in:
Bibliographic Details
Main Authors: Vadim Mett, Oleg V. Kurnasov, Ivan A. Bespalov, Ivan Molodtsov, Craig M. Brackett, Lyudmila G. Burdelya, Andrei A. Purmal, Anatoli S. Gleiberman, Ilia A. Toshkov, Catherine A. Burkhart, Yakov N. Kogan, Ekaterina L. Andrianova, Andrei V. Gudkov, Andrei L. Osterman
Format: article
Language:EN
Published: Nature Portfolio 2021
Subjects:
Biology (General)
QH301-705.5
Online Access:https://doaj.org/article/bcafc6dab7b74c02bc2aec45e9ac993a
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doaj.org/article/bcafc6dab7b74c02bc2aec45e9ac993a

Similar Items